Puig stock heads toward October sales update at EUR 18.19

Published on 10/07/2026 at 14:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bestinver lifted its Puig target to EUR 20.00 from EUR 18.50 on October 6, 2026. First-half sales exceeded EUR 2.3 billion before the October 21 update.

Puig, ES0105777017, Illustration mit AI erstellt.

Puig stock (ISIN ES0105777017) was trading at EUR 18.19 on BME on October 7, 2026 at 2:08 p.m. CEST, down 0.44 percent from the previous close. The immediate catalyst is a higher valuation from Bestinver Securities, which raised its price target to EUR 20.00 from EUR 18.50 on October 6, 2026, while keeping a Buy rating.

Bestinver raises its target

According to Estrategias de Inversion, Bestinver's new EUR 20.00 target compares with the EUR 18.50 valuation published previously. The firm retained its Buy recommendation, making the target revision a valuation signal rather than a change in stance.

The market is still pricing in a demanding recovery path. Puig's share price of EUR 18.19 stood 3.7 percent below its 52-week high of EUR 18.89, while the 52-week low was EUR 13.11 on the same market-data reference.

Sales update sets the next test

Puig's next company checkpoint is its third-quarter sales update on October 21, 2026. Estrategias de Inversion also identifies October 28, 2026 as the date for Puig's Capital Markets Day.

The latest reported operating scale provides the benchmark for that update. El Periodico reported that Puig generated more than EUR 2.3 billion in sales during the first half of 2026, with perfumery accounting for almost three quarters of its business. That mix leaves fragrance execution and the contribution from skincare brands central to the October sales figure.

Puig stock stays below its yearly high

Puig's market capitalization was EUR 10.2 billion on October 7, 2026, while the stock traded within a 52-week range of EUR 13.11 to EUR 18.89. The combination of a positive target revision and a price below the annual high puts the October sales update at the center of the valuation debate.